ABSTRACT
Background. The COVID-19 virus infection can develop ocular manifestations. Purpose. To report a case of a coats disease patient who was evaluated one week before as part of a routine retinal consultation and later had COVID-19 with sudden loss of vision in one eye. Material and Methods. The affected eye had a visual acuity of 20/400. At fundus examination abnormal tortuous vasculature, hemorrhages, branch retinal vein occlusion and macular edema were found. It was confirmed with fluorescein angiography and optical coherence tomography. Results. With a combined therapy of intravitreal Aflibercept, periocular triamcinolone and focal laser was recovery the visual acuity to 20/20. Conclusion. There are few cases described in literature, but a sudden loss of vision during a COVID-19 infection must be early detected and treated to achieve a better visual acuity recovery. © Leopoldo Garduño Vieyra, Raúl Rúa Martínez, Bruno Flores Escobar, 2022.
ABSTRACT
SARS-CoV-2 is a novel RNA coronavirus responsible of a deadly pandemic: the clinical illness COVID-19. With only one authorized drug for emergency use in critically ill patients: Remdesivir, there is not any other approved drug or vaccine yet with proven potential to overcome this infection. We exposed here many scientific evidences to support our novel idea that a macrolide, basically Clarithromycin, could be effective as a single agent for treatment and prophylaxis of COVID-19. Clarithromycin could change the history of this pandemic. It could reduce the costs of treatment and the potential adverse effects when combining more than one drug such as with Hydroxychloroquine. Clarithromycin treatment and prophylaxis as a single agent could be much more simple, safe and cheaper as giving Chloroquine or Hydroxychloroquine alone or in combination with Azithromycin as well as other therapeutic options.